An interventional study of Variation of Pressure Support Levels in Acute Hypoxemic Respiratory Failure and Mechanical Ventilation Complication, sponsored by Centre for Medical Sciences. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-05.
Sponsored by Centre for Medical Sciences · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 112 studies in Respiratory Insufficiency with a site in Italy — 27 open to participants now, 28 under way, 2 of them phase 3. Respiratory Insufficiency · Italy.
Among the 112 studies in Respiratory Insufficiency with a site in Italy, this one is the 41st largest by planned enrollment of the 65 interventional ones that give a count, is one of 8 that started in 2025, is one of 51 with no phase, reaches primary completion later than 24 of the 27 other live ones, and was the 106th registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →27 of the 112 studies in Respiratory Insufficiency with a site in Italy are open now. Recruiting first, the newest first:
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 18+
Istituto Clinico Humanitas · Sites in Italy
Ages 18+
Università Vita-Salute San Raffaele · Sites in Italy
Ages 65+ · Healthy volunteers
Istituto Giannina Gaslini · Sites in Italy
Ages 18+ · Men only
Medipol University · Sites in Italy, Chile, Egypt and 3 more countries
Ages 18–89
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
112 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 55 across the 65 interventional studies, 93 across the 45 observational. Of the 65 that completed or were terminated, 4 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 112 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Centre for Medical Sciences as lead sponsor.
Centre for Medical Sciences has 1 study filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
7 of the studies in Respiratory Insufficiency with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07098611Medipol UniversityA New Tool for Extubation Readiness in Mechanically Ventilated Patients: Readiness for EXtubation Score | 2026-12-30 |
| NCT06511583Azienda Ospedaliero-Universitaria CareggiFBS-ASaP: Fibrobronchoscopy in ASpiration Pneumonia in the Emergency Department | 2027-02-05 |
| NCT07175194Istituto Clinico HumanitasAssociation Between EIT and CT During PEEP Titration in Patients With Acute Respiratory Failure | 2027-03 |
| NCT05440851University Health Network, TorontoPlatform of Randomized Adaptive Clinical Trials in Critical Illness | 2027-03-31 |
| NCT06001645Università Vita-Salute San RaffaeleLaboratory Biomarkers and Pulmonary Interstitial Emphysema in ARDS (PIE-ARDS) | 2027-04 |
Add all 7 to your calendar (.ics) → With an account.
Among the 112 studies in Respiratory Insufficiency with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The TEMA study (Targeting prEssure-Muscle-index to avoid ventilatory over-Assistance during pressure support ventilation) is a prospective, interventional crossover trial investigating the relationship between pressure support (PS) and tidal volume (Vt) in ICU patients with acute hypoxemic respiratory failure (AHRF) receiving pressure support ventilation (PSV). The study aims to assess whether the Pressure-Muscle Index (PMI)-a marker derived from the difference between plateau and peak inspiratory pressure-can help identify the optimal level of ventilatory assistance, preventing over-assistance and its associated complications such as diaphragm atrophy and patient self-inflicted lung injury (P-SILI). By exploring the sigmoidal relationship between PS and Vt, the study seeks to define a physiological threshold (PMI=0) that may serve as a personalized target for PSV titration.
The TEMA study is a prospective, interventional crossover trial designed to explore the physiological relationship between levels of pressure support (PS) and tidal volume (Vt) in mechanically ventilated ICU patients diagnosed with acute hypoxemic respiratory failure (AHRF). The goal is to identify a pressure support threshold beyond which over-assistance occurs, leading to excessive tidal volumes and suppression of respiratory muscle activity.
The central hypothesis is that the PS-Vt curve follows a sigmoidal pattern: an initial plateau phase with stable Vt is followed by a steep, compliance-driven increase in Vt at higher PS levels. The Pressure-Muscle Index (PMI), calculated as the difference between plateau pressure (Pplat) and peak airway pressure (Ppeak) during an inspiratory occlusion, is used to define this inflection point (PMI=0), which marks the transition from physiologically appropriate to excessive assistance.
Study Design: The study is conducted at the ICU of Santa Chiara Hospital (Trento, Italy) and includes seven levels of pressure support modulation-three above and three below the identified PMI=0 point. At each level, key physiological variables such as Vt, respiratory rate (RR), minute ventilation, PMI, and patient-ventilator asynchrony index are recorded.
A second evaluation between days 4-6 post-enrollment is planned for patients who remain intubated, to assess whether the PS-Vt relationship evolves over time, reflecting changes in respiratory drive and mechanics during the ICU course.
Technical Aspects:
Measurements include respiratory system compliance, work of breathing (WOB), inspiratory effort, and occlusion-based indices.
PS levels are applied in randomized order to minimize bias. Clinical PSV settings are reinstated between steps to avoid carryover effects and ensure patient safety.
Analytical Approach: The primary outcome is to characterize the PS-Vt relationship and validate the use of PMI as a physiological marker of the optimal support threshold. Nonlinear regression models, including sigmoidal curve fitting, will be used to identify inflection points (c parameters) in the PS-Vt curve. A Monte Carlo simulation informed the sample size, targeting 36 patients to account for potential dropouts, ensuring >90% power to detect a meaningful breakpoint.
Multivariable models will adjust for potential confounders such as PaCO₂, sedation depth, BMI, and baseline compliance.
Expected Impact: If successful, the TEMA study will provide a new physiologically grounded framework for tailoring pressure support in assisted ventilation. By validating PMI as a real-time bedside tool, the study may support a more personalized approach to weaning and ventilation management, potentially improving outcomes such as duration of ventilation, weaning success, and ICU stay.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The PS level at which PMI is zeroed, meaning the patient's inspiratory effort contributes minimally to tidal volume
Procedure: Variation of Pressure Support Levels
Above PSPMI=0: +2 cmH₂O above PSPMI=0 (over-assistance zone).
Procedure: Variation of Pressure Support Levels
Above PSPMI=0: +4 cmH₂O above PSPMI=0 (over-assistance zone).
Procedure: Variation of Pressure Support Levels
Above PSPMI=0: +6 cmH₂O above PSPMI=0 (over-assistance zone).
Procedure: Variation of Pressure Support Levels
Below PSPMI=0: -2 cmH₂O below PSPMI=0 (under-assistance zone).
Procedure: Variation of Pressure Support Levels
\- Below PSPMI=0: -4 cmH₂O below PSPMI=0 (under-assistance zone).
Procedure: Variation of Pressure Support Levels
\- Below PSPMI=0: -6 cmH₂O below PSPMI=0 (under-assistance zone).
Procedure: Variation of Pressure Support Levels
Patients will undergo six randomized PS levels (+2, +4, +6 cmH₂O above and -2, -4, -6 cmH₂O below PSPMI=0).
Pressure Support-Tidal Volume (PS-Vt) Relationship
The primary aim is to determine whether the PS-Vt curve exhibits a flat region (where tidal volume remains stable) before transitioning into a steep, compliance-dependent increase at higher PS levels. This transition point, identified as PSPMI=0, is hypothesized to represent the threshold for over-assistance.
Time frame: Up to 5 minutes after each PS level adjustment during the interventional phase (Day 1)
Validation of Pressure-Muscle Index (PMI) as an Over-Assistance Marker
PMI will be tested as a real-time bedside indicator for detecting over-assistance in PSV. The study will assess whether PMI=0 reliably corresponds to the threshold of over-assistance, characterized by a minimal patient contribution to Vt and a linear increase in Vt proportional to PS.
Time frame: Up to 5 minutes after each PS level adjustment during the interventional phase (Day 1) and during follow-up assessment on Days 4-6 (if patient remains intubated)
Impact of Respiratory Mechanics on PS-Vt Relationship
Evaluation of how respiratory compliance (Crs) influence the PS-Vt curve. The study will investigate individual variations in ventilatory response to PS.
Time frame: During the interventional phase on Day 1 and during follow-up assessment on Days 4-6 (if patient remains intubated)
Rate of Ineffective Efforts During Over-Assistance
Quantification of ineffective respiratory efforts (i.e., inspiratory efforts not followed by ventilator-triggered breaths) during PS levels exceeding the identified PSPMI=0 threshold.
Time frame: Up to 5 minutes after each PS level adjustment during the interventional phase (Day 1) and during follow-up assessment on Days 4-6 (if patient remains intubated)
Effect of Over-Assistance on Ventilatory Asynchronies
Measurement of the asynchrony index (percentage of breaths with any form of patient-ventilator asynchrony) at different levels of pressure support, particularly above PSPMI=0.
Time frame: Up to 5 minutes after each PS level adjustment during the interventional phase (Day 1) and during follow-up assessment on Days 4-6 (if patient remains intubated)
Weaning failure
Defined as the inability to transition from PSV to unassisted breathing, requiring either reintubation, prolonged PSV dependence, or failure of a spontaneous breathing trial (SBT). The rate of weaning failure will be compared between patients receiving higher vs. lower levels of PSV support.
Time frame: Up to 100 months or until the of death from any cause, whichever came first.
Duration of mechanical ventilation
Total number of days on invasive mechanical ventilation (IMV), including both fully controlled and pressure-supported modes. The study will compare patients requiring different levels of PSV assistance.
Time frame: From date of randomization until the date of extubation or date of death from any cause, whichever came first, assessed up to 100 months
ICU length of stay (LOS)
Total duration (in days) of ICU admission, analyzing whether PSV settings influence prolonged ICU stays due to delayed weaning, respiratory complications, or ventilatory asynchronies
Time frame: Up to 100 months or until the of death from any cause, whichever came first.
Hospital length of stay (LOS)
Total number of days spent in the hospital from admission to discharge, evaluating whether PSV-related ventilatory strategies impact overall hospitalization duration and recovery time.
Time frame: Up to 100 months or until the of death from any cause, whichever came first.
Impact of Respiratory Mechanics on PS-Vt Relationship
Evaluation of how respiratory drive influence the PS-Vt curve. The study will investigate individual variations in ventilatory response to PS.
Time frame: From the randomization to 5 minutes.
Impact of Respiratory Mechanics on PS-Vt Relationship
Evaluation of how patient effort (Pmus) influence the PS-Vt curve. The study will investigate individual variations in ventilatory response to PS.
Time frame: From the randomization to 5 minutes.
Spontaneous breathing failure
Defined as the Number of Participants who fail transition from PCV to PSV.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Jun 2028, 32 months after the start.
Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 32 months is above that.
Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.